ARTHROPLASTY
Heterotopic ossification prophylaxis with etoricoxib versus diclofenac after THA
Int Orthop. 2016 Apr;40(4):673-80100 patients scheduled for total hip arthroplasty were randomized to one of two different oral non-steroid anti-inflammatory drugs (NSAIDs) for heterotopic ossification (HO) prophylaxis; etoricoxib or diclofenac. Patients were assessed over a 6 -month follow-up for the development of HO. Results demonstrated no significant differences between groups in the development of HO. No patient of either group was observed to develop Brooker grade 3 or 4 HO.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
